Specifically, five cell lines with different p53 statuses were used: GP5d colon adenocarcinoma cells (henceforth GP5d) expressing wild-type (WT) p53, GP5d cells with p53-depletion (p53-KO)27, OE19 esophageal cancer cells harboring a mutation in the exon 9 of TP53 gene (c.928_930insA, p.N310fs26X)28, LNCaP-1F5 prostate adenocarcinoma cells, and LNCaP-1F5 cells with p53 deletion. Here, TP53 is linked to prostate adenocarcinoma.